Somberg J C, Butler B, Flowers D, Keefe D, Torres V, Miura D
Am J Cardiol. 1984 Aug 13;54(4):43B-48B. doi: 10.1016/0002-9149(84)90823-3.
One hundred patients with inducible ventricular tachycardia (VT) on electrophysiologic studies underwent serial drug testing with procainamide, lidocaine and lorcainide to determine comparative efficacy. Acute intravenous administration was followed by repeat programmed electrical stimulation (PES) studies on separate days for each antiarrhythmic agent. Lorcainide prevented VT induction in 69% of the 100 patients studied, procainamide in 50% of the 75 patients studied and lidocaine in 30% of 53 patients. After PES and serial drug testing, 46 patients were started on lorcainide, 9 on procainamide and 45 on other antiarrhythmic drug regimens. Eighty percent of the patients have remained on lorcainide therapy, whereas 47% have continued on other drug therapies started over 17.5-month mean follow-up period. Despite sleep-wake disturbances and a need for sedation at night, lorcainide therapy was well tolerated in this population and remained an effective antiarrhythmic agent with prolonged administration.
100例在电生理检查中诱发出室性心动过速（VT）的患者接受了普鲁卡因胺、利多卡因和劳卡尼的系列药物测试，以确定其相对疗效。每种抗心律失常药物在急性静脉给药后，于不同日期重复进行程控电刺激（PES）研究。在100例接受研究的患者中，劳卡尼使69%的患者VT诱发受到抑制；在75例接受研究的患者中，普鲁卡因胺使50%的患者VT诱发受到抑制；在53例患者中，利多卡因使30%的患者VT诱发受到抑制。经过PES和系列药物测试后，46例患者开始使用劳卡尼治疗，9例使用普鲁卡因胺，45例使用其他抗心律失常药物方案。80%的患者继续接受劳卡尼治疗，而在平均17.5个月的随访期内，47%的患者继续接受开始使用的其他药物治疗。尽管存在睡眠-觉醒障碍且夜间需要镇静，但该人群对劳卡尼治疗耐受性良好，长期给药时它仍是一种有效的抗心律失常药物。
